David Oberlin, M.D.
NPI 1376924902 · Dermatology Physician · Grand Rapids, MI
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1376924902
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- 4301117195 (MI)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
11 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
3 documented practice locations
- Medicare service volume (vs. specialty peers)25% of score
3,680 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 1,436 | $6 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 445 | $45 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 444 | $90 |
| Biopsy of Related Skin Growth, First Growth11102 | 300 | $81 |
| Destruction of Skin Growth, 1-14 Growths17110 | 268 | $105 |
| Biopsy of Related Skin Growth, Each Additional Growth |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 24 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Ketoconazole | 285 | 171 |
| Clobetasol Propionate | 261 | 155 |
| Triamcinolone Acetonide | 173 | 113 |
| Fluorouracil | 148 | 136 |
| Hydrocortisone | 126 | 86 |
| Mupirocin | 98 | 72 |
| Betamethasone Dipropionate | 97 | 66 |
| Doxycycline Hyclate | 95 | 82 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$4,774 across 156 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Additional practice locations (2)
- 1600 S Beacon Blvd Ste 160Grand Haven, MI 49417-2654Phone: (616) 268-2001Fax: (616) 268-2002
- 1761 W M 43 Hwy Ste 2Hastings, MI 49058-8567Phone: (269) 945-5363Fax: (269) 945-0405
Registry dates
- Enumerated
- 2015-06-09
- Last updated
- 2024-01-12
- Certified
- 2024-01-12
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.